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Introduction
The pathogenesis of essential hypertension is believed to be mul-
tifactorial and under the influence of multiple genetic and environ-
mental factors. Genes associated with blood pressure (BP) are not 
sufficiently known as yet. A recent genome-wide association study 
Original Article
http://dx.doi.org/10.4070/kcj.2013.43.1.13
Print ISSN 1738-5520 • On-line ISSN 1738-5555
Association between Serine/Threonine Kinase 39 Gene Polymorphism, 
Hypertension, and Other Cardiovascular Risk Factors in Koreans
Dong-Jik Shin, PhD1, Sang-Hak Lee, MD2, Sungha Park, MD2, and Yangsoo Jang, MD2
1Cardiovascular Genome Center, Yonsei University Health System, Seoul, 
2Cardiology Division, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea
Background and Objectives: Although the association between single nucleotide polymorphisms (SNPs) of Serine/Threonine Kinase 39 
(STK39) and hypertension has been reported, the prior studies have been inconsistent. The aim of this study is to evaluate the association 
between rs3754777 and rs6749447, the two SNPs of STK39, and hypertension and other cardiovascular risk factors in Koreans, residing in 
the Republic of Korea.
Subjects and Methods: We included 238 hypertensive patients and 260 controls. The associations between genotype and haplotype com-
bination and hypertension were examined. In addition, possible SNP-related differences in the adjusted blood pressure and other cardiovas-
cular risk factors were analyzed.
Results: There was no significant association between the two SNPs and hypertension. However, the carriers of AA genotype of rs3754777 
showed lower blood glucose and cholesterol levels, particularly in females. Genotype of rs6749447 was associated with the waist circum-
ference, triglyceride, and high density lipoprotein-cholesterol levels, only in gender-stratified analysis. The effects of haplotype combina-
tions on risk factors were compatible with genotype effects of each SNP.
Conclusion: Associations between the two SNPs of STK39, rs3754777 and rs6749447, and hypertension were not significant. However, the 
two SNPs showed genotype-related differences in blood glucose, lipids, and waist circumference, especially in women. Further studies are 
needed to clarify the effect of STK39 variants in these cardiovascular risk factors. (Korean Circ J 2013;43:13-22)
KEY WORDS: STK39 protein, human; Hypertension; Cholesterol; Waist circumference; Glucose.
Received: May 23, 2012
Revision Received: June 11, 2012
Accepted: September 17, 2012
Correspondence: Sang-Hak Lee, MD, Cardiology Division, Department of 
Internal Medicine, Severance Cardiovascular Hospital, Yonsei University 
College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea
Tel: 82-2-2228-8461, Fax: 82-2-2227-7732
E-mail: shl1106@yuhs.ac
• The authors have no financial conflicts of interest.
This is an Open Access article distributed under the terms of the Creative 
Commons Attribution Non-Commercial License (http://creativecommons.
org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work 
is properly cited.
examined single nucleotide polymorphisms (SNPs) in American Old 
Order Amish and identified SNPs in the Serine/Threonine Kinase 39 
(STK39) that were associated with hypertension.1) STK39 encodes a 
serine/threonine kinase known as a Ste20-related proline-rich ki-
nase (SPAK), one of STE20 family. These kinases were shown to in-
teract with WNK kinases and cation-chloride cotransporters, and it 
was suggested that their functional change may cause BP dysregul-
ation.1) SPAK also is related to cytoskeletal rearrangement, mitogen 
activated protein (MAP) kinases, and inflammation.2) Associations 
between the above mentioned SNPs and different STK39 SNPs and 
BP were confirmed in other Caucasian and Chinese cohorts.3)4) How-
ever, the influence of STK39 polymorphism on BP has been incon-
sistent, and the effects of the variants have not been found in other 
large studies.5-7) Although a few studies have been conducted to 
replicate the results in the Asian population, the association between 
STK39 variants and hypertension is still unclear in Asians. 
Here we examined the effect of rs3754777 and rs6749447, the 
two representative SNPs of STK39, on hypertension in a South Kore-
an cohort of 238 hypertensives and 260 controls. The primary pur-
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pose was to evaluate the association between the two SNPs and the 
risk of hypertension in females and males. In addition, we investi-
gated the effects of the SNPs on other cardiovascular risk factors. 
In the present study, we found no significant association between 
the studied SNPs and hypertension. However, the two SNPs showed 
genotype-related differences in blood cholesterol, glucose levels, and 
waist circumference, especially in women. Our study is the first to 
systemically analyze the association between STK39 variants and 
multiple cardiovascular risk factors.
Subjects and Methods
Study population
We included 238 consecutive hypertensive patients along with 
age- and sex-matched 260 healthy controls. Patients were drawn 
from the Cardiovascular Genome Center registry, Yonsei University 
Health System. All consecutive patients who visited Severance Car-
diovascular Hospital, Seoul, Korea were prospectively screened for 
hypertension. We recruited patients who had systolic BP greater 
than 135 mm Hg and/or diastolic BP greater than 85 mm Hg, before 
taking antihypertensive medications, during the three different. Pa-
tients who had already taken antihypertensive medications were 
also enrolled. Hypertensive patients who were diagnosed at 30-60 
years of age were eligible for enrollment. The control subjects were 
recruited during the health check-up at the Health Promotion Cen-
ter, Yonsei University Health System, Seoul, Korea. They were match-
ed for sex and age (±5 years) and selected from subjects without 
history of hypertension. Control subjects had to have systolic BP 
<135 mm Hg and diastolic BP <85 mm Hg, without BP-lowering ag-
ents. Criteria for exclusion included structural heart disease, coro-
nary artery disease, secondary hypertension, diabetes mellitus, or 
serum creatinine >1.4 mg/dL. The purpose of the study was thor-
oughly explained to all subjects, and the informed consent was 
obtained. The local institutional review board approved this study.
Clinical data collection and blood sample analysis
On the day of enrollment, clinical data including demographic va-
riables, medical history, and antihypertensive medications were re-
corded. BP was measured by trained nurses at the right brachial ar-
tery, using a mercury sphygmomanometer. Subjects had 10 minutes 
of rest in the supine position before the measurements, and the av-
erage of at least three measurements were used in the study. To ad-
just for the drug effects, 8/4, 14/10, and 20/16 mm Hg were added 
to the measured systolic BP/diastolic BP of patients taking one, two, 
or three antihypertensive drugs, respectively.3) Venous blood samples 
were collected after an overnight fast, and samples were analyzed 
within 4 hours of collection. All analyses were conducted by a local 
laboratory, certified by the Korean Society of Laboratory Medicine. 
Genotyping
Genomic deoxyribonucleic acid (DNA) was extracted from 5 mL of 
peripheral venous blood using a commercially available isolation kit 
(QuickGene SP Kit DNA Whole blood, Fujifilm, Tokyo, Japan). Based 
on prior reports1) on variants in STK39, two relevant polymorphisms, 
rs3754777 and rs6749447, were selected for analysis. Genotyping 
was performed using the TaqMan fluorogenic 5’ nuclease assay (ABI, 
Foster City, CA, USA). 
Statistical analysis
Group differences in the categorical variables, genotypes, and ha-
plotypes were assessed by chi-square test, and continuous variables 
were examined by Student’s t-test. The association between geno-
type and hypertension was evaluated using the odds ratios, 95% 
confidence intervals of the chi-square test, and logistic regression 
analysis. Possible genotype-related differences in BP and other car-
diovascular risk factors were analyzed by Kruskal-Wallis test. Results 
are expressed as mean±SD or median (interquartile range) and 
2-tailed value of p<0.05 was considered statistically significant. All 
data were analyzed using Statistical Package for the Social Sciences 
(SPSS) 17.0 (SPSS Inc., Chicago, IL, USA). 
Results
Characteristics and allele frequencies of the study population
The characteristics of the study population are presented in Table 
1. The average age was 50 years, and the ratio of female subjects 
was 50%. Individuals with hypertension were more likely to have 
clinical features of metabolic syndrome: higher waist circumference, 
BP, blood glucose, triglyceride, and lower high density lipoprotein-
cholesterol (HDL-C) levels. Two and fifteen subjects were taking glu-
cose lowering and lipid lowering agents, respectively. 
Minor allele frequencies were 0.206 and 0.319 for rs3754777 and 
rs6749447, respectively. The genotype and haplotype distributions 
of STK39 polymorphisms were not different between normotensive 
controls and hypertensive patients (Table 2). 
Relationship between studied variants and hypertension
The relationship between hypertension risk and genotypes or ha-
plotypes of STK39 in females and males are presented in Table 3. No 
association between genotypes and hypertension risk in any group 
reached statistical significance. The association in a subgroup of yo-
ung subjects (<50 years old) was also significant (Supplementary 
Table 1). Likewise, the risks of hypertension were not different be-
tween the haplotype combinations, although A-C/A-C haplotype sh-
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owed a tendency to have hypertension in the female subgroup. 
Relationship between studied variants, blood pressure, and 
cardiovascular risk factors
Mean±SD or median (interquartile range) and Kruskal-Wallis an-
alysis p for cardiovascular risk factors for all genotypes are listed in 
Table 4. Adjusted systolic and diastolic BP were similar between all 
genotypes in both rs3754777 and rs6749447 variants. However, rs 
3754777 showed significant genotype-related differences for glu-
cose and total cholesterol. Subjects with AA genotype had lower 
glucose and cholesterol levels. In analyses stratified by the gender, 
this difference was statistically significant only in females. In anal-
yses of subgroups not taking glucose or lipid lowering agents, the 
associations showed only minimal changes (p were 0.055 and 0.03 
with regard to glucose and total cholesterol, respectively) (Supple-
mentary Table 2). Low density lipoprotein-cholesterol (LDL-C) was 
lower in females with AA genotype of rs3754777. The genotype of 
rs6749447 was not related to specific risk factors. However, in gen-
der-stratified analyses, AA genotype of rs6749447 showed lower 
waist circumference compared to other genotypes in females. In 
males, AA genotype revealed higher triglyceride and lower HDL-C 
levels. 
Association between STK39 rs3754777A-rs6759557C haplotype 
combinations and cardiovascular risk factors are largely compatible 
with those between the genotypes and risk factors (Supplementary 
Table 3). For instance, haplotype combination A-C was associated 
with lower glucose and total cholesterol values. Other gender-strati-
Table 1. Characteristics of the study subjects   
 Normotensive (n=260) Hypertensive (n=238)  p
Age (years) 51 (45-57) 50 (45-55) 0.40
Female gender (%) 129 (49.6) 120 (50.4) 0.86
Waist circumference (cm) 81 (77-86) 83 (78-88) <0.01
Metabolic syndrome (%) 44 (16.9) 92 (38.7) <0.01
Blood pressure (mm Hg)
Systolic BP 120 (110-130) 130 (117-143) <0.01
Diastolic BP 80 (70-85) 84 (80-90) <0.01
Systolic BP, adjusted 120 (110-130) 138 (126-150) <0.01
Diastolic BP, adjusted 80 (70-85) 90 (84-100) <0.01
Laboratory values
Glucose (mg/dL) 82 (78-89) 85 (78-94) 0.03
Total cholesterol (mg/dL) 199 (175-225) 196 (175-220) 0.31
Triglycerdie (mg/dL) 103 (77-158) 122 (85-180) 0.01
HDL-C (mg/dL) 50 (42-60) 47 (38-58) 0.02
LDL-C (mg/dL) 122 (102-146) 118 (100-139) 0.15
hs-CRP (mg/L) 0.38 (0.22-0.77) 0.71 (0.29-1.85) <0.01
Medications (%)
Antihypertensive agent 0 (0) 183 (76.9) <0.01
Glucose lowering agent 1 (0.4) 1 (0.4) 1.00
Lipid lowering agent 2 (0.7) 13 (5.5) <0.01
Values are median (interquartile range) or n (%). BP: blood pressure, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol, 
hs-CRP: high sensitivity C-reactive protein




GG 0.641 0.619   








G-C 0.475 0.471 0.86
G-A 0.326 0.311 0.64
A-C 0.199 0.218 0.45
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fied findings are listed in the same table. 
Discussion
In the current study, we found no association between two SNPs, 
rs3754777 and rs6749447, located within STK39 and hypertension 
in a cohort of 498 Koreans. Although there was no implication of th-
ese SNPs on adjusted BPs, they were associated with other cardio-
vascular risk factors. The carriers of AA genotype of rs3754777 had 
lower blood glucose and cholesterol levels. This relationship was 
more obvious in females. Although genotype of rs6749447 was not 
related to specific risk factors, it was associated with waist circum-
ference, triglyceride, and HDL-C levels in gender stratified analysis. 
Association between haplotype combination of studied SNPs and 
risk factors were compatible with genotype-risk factor relationship 
of each SNP. 
Polymorphisms of STK39 were reported to be associated with BP 
first in Caucasian samples.1) In the meta-analysis combining four 
studies, Wang et al.1) showed the effects of SNPs of rs6749447 and 
rs3754777 on BP. Another SNP of STK39, rs35929607, was also re-
lated to the hypertension prevalence in women of two cohorts in 
Swedes.3) In the Chinese population, two SNPs of STK39, rs6433027 
and 3754777, were found to be associated with hypertension.4) 
In the results of this study, the associations between STK39 SNPs 
and hypertension or BP were not significant. Although the reason 
for the discrepancy is not clear, several possibilities may be suggest-
ed. First, all the samples were of Koreans residing in the Republic of 
Korea, and the STK39-BP relationship may be weaker in this popula-
tion. The influence of STK39 polymorphism on BP has not been con-
sistently confirmed. In the two large GWAS, using more than 60000 
people, the effects of STK39 SNPs on BP were not found.5)6) In addi-
tion, in one British7) and one Chinese8) study, variants of STK39 were 
not associated with BP. Recently, Rhee et al.9) reported four previ-
ously reported SNPs associated with salt-sensitivity in 101 Koreans. 
However, in that study, no polymorphism of STK39 showed signifi-
cant effects after adjusting for confounding factors. Second, alth-
ough STK39 gene encodes for a protein that plays a role in BP regul-
ation, its final effects may be too small to be detected consistently 
in every study cohort. Third, as the population size of this study is not 
sufficiently large, it cannot be completely ruled out that some va-
riants with impacts may not have obtained statistical significance. 
We found significant associations between STK39 variants and 
cardiovascular risk factors other than BP. They include glucose, total 
cholesterol, and LDL-C in rs3754777; and waist circumference, tri-
glyceride, and HDL-C in rs6749447. Four of the factors belong to the 
characteristics of metabolic syndrome. The minor allele carriers of 
rs3754777 had the tendencies to have lower levels of risk factors. 
Those of rs6749447 showed contradictory results on waist circum-
ference and triglyceride and HDL-C. Thus, it is difficult to tell what 
clinical association the genotype of the latter STK39 SNP may finally 
have. However, to our knowledge, this study is the first to demon-
strate the association between STK39 variants and the above fac-
tors. In a prior study by Wang et al.,1) it was mentioned that STK39 
SNPs were modestly associated with blood glucose level, insulin re-
sponse to glucose, and triglyceride level in a subset of Amish popul-
ation. In addition, two other STK39 SNPs were reported to be linked 
to multiple phenotypes of metabolic syndrome.10) In the present stu-
dy, we have shown the relationship between STK39 SNPs and car-
diovascular risk factors more systemically. It has been known that 
STK39 was located in an area in which BP, obesity, and diabetes-re-
lated rodent quantitative trait loci have been mapped. Furthermore, 
STK39/SPAK is able to activate the p38 MAP kinase pathway, provid-
ing evidence that it can act as a stress-mediated signals.11)12) It has 
been recently demonstrated that p38 MAP kinase plays a role in glu-
cose13) and lipoprotein metabolism,14) and this may support the bio-
logical mechanism of the current data. Although investigating the 
functional mechanism of STK39 is beyond the scope of this study, 
further projects focusing on this issue may unveil the role of this gene 
on multiple cardiovascular risk factors. 
In this study, the influence of STK39 variants on the risk factors 
Table 3. Relative risk for hypertension based on genotype and haplotype of the studied variants
Total Female Male
OR  95% CI  p OR 95% CI  p OR 95% CI  p
Genotype
rs3754777 AA vs. GA+GG 1.38 0.56-3.34 0.48 1.27 0.33-4.91 0.10 1.39 0.41-4.69 0.60
rs6749447 AA vs. CA+CC 1.07 0.60-1.89 0.83 0.67 0.31-1.49 0.33 1.81 0.76-4.27 0.18
Haplotype (rs3754777-rs6749447)
A-C/A-C vs.  A-C/Other+Other/Other 1.12 0.77-1.64 0.55 1.64 0.96-2.82 0.07 0.78 0.45-1.33 0.36
G-A/G-A vs. G-A/Other+Other/Other 0.87 0.60-1.25 0.45 0.74 0.44-1.24 0.26 1.02 0.60-1.72 0.95
G-C/G-C vs. G-C/Other+Other/Other 1.03 0.68-1.55 0.90 1.04 0.57-1.90 0.90 1.04 0.59-1.82 0.89
OR: odds ratio, CI: confidence interval
17Dong-Jik Shin, et al.
http://dx.doi.org/10.4070/kcj.2013.43.1.13www.e-kcj.org
Table 4. Association of genotype of the studied variants and parameters of cardiovascular risk
Genotype
Total Female Male
Values p Values p Values  p
rs3754777
Waist circumference 0.17 0.07 0.65
AA 79.8±7.0 75.5±6.8 83.7±4.7
GA+GG 82.0±6.9  79.5±6.6 84.7±6.2
Systolic BP, adjusted 0.44 0.14 0.78
AA 126 (113-138) 123 (111-128) 133 (118-148)
GA+GG 130 (118-142) 129 (114-142) 130 (119-143)
Diastolic BP, adjusted 0.45 0.81 0.22
AA 89 (75-97) 84 (74-90) 96 (80-100)
GA+GG 84 (76-92) 81 (74-90) 84 (80-94)
Glucose 0.049 0.02 0.59
AA 78 (74-86) 78 (72-81) 82 (74-110)
GA+GG 84 (78-91) 82 (77-89) 86 (79-94)
Total cholesterol 0.04 0.04 0.41
AA 183 (157-205) 177 (158-197) 189 (155-212)
GA+GG 198 (175-222) 202 (178-227) 195 (174-213)
Triglyceride 0.20 0.60 0.23
AA 97 (77-153) 98 (81-106) 82 (75-188)
GA+GG 112 (82-164) 101 (77-150) 126 (89-182)
HDL-C 0.71 0.39 0.91
AA 49 (46-57) 56 (47-64) 47 (36-52)
GA+GG 48 (40-59) 52 (43-62) 45 (38-54)
LDL-C 0.12 0.047 0.79
AA 108 (96-131) 99 (96-125) 111 (96-140)
GA+GG 120 (101-142) 121 (103-146) 118 (99-138)
hs-CRP 0.52 0.67 0.45
AA 0.72 (0.22-1.12) 0.64 (0.22-1.12) 0.78 (0.55-3.31)
GA+GG 0.45 (0.23-1.14) 0.39 (0.18-0.95) 0.55 (0.30-1.46)
rs6749447
Waist circumference 0.13 0.04 0.84
AA 80.7±7.3 77.1±6.6 84.9±5.6
CA+CC 82.2±6.9 79.8±6.7 84.7±6.3
Systolic BP, adjusted 0.17 0.11 0.84
AA 123 (110-145) 118 (102-139) 124 (116-147)
CA+CC 130 (118-142) 129 (115-141) 130 (119-142)
Diastolic BP, adjusted 0.47 0.26 0.77
AA 80 (75-91) 80 (69-90) 84 (80-98)
CA+CC 84 (76-93) 83 (74-90) 85 (80-95)
Glucose 0.63 0.68 0.76
AA 82 (79-91) 81 (77-90) 86 (81-91)
CA+CC 84 (78-91) 82 (77-89) 85 (78-94)
Total cholesterol 0.50 0.50 0.69
AA 193 (174-219) 198 (174-219) 185 (170-220)
CA+CC 198 (175-222) 202 (177-226) 195 (175-213)
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was clearer in women. This finding is in accordance with prior stu-
dies that have shown gender-dependency of STK39 effect. In the 
study by Fava et al.,3) the association of STK39 rs35929607 variant 
and hypertension was evident only in women. However, in the study 
by Chen et al.,4) STK39 rs6433027 and rs3754777 had more signifi-
cant association with hypertension in male. Sex differences in hy-
pertension may be attributed to multiple factors such as lifestyle, 
diet, and genetic polymorphism.15) Interestingly, it has been docu-
mented that SPAK expression is affected by both androgen and es-
trogen in human prostate cancer cells.16) Nevertheless, further stud-
ies are needed to clarify the underlying mechanism of gender de-
pendency in STK39 effect on cardiovascular risk factors. 
The present study has several limitations. Although rs3754777 
and rs6749447 were the first variants known to be hypertension 
susceptible in STK39 gene, other SNPs have been reported to have 
effects thereafter. Inclusion of more STK39 variants in the study 
may have been helpful to understand the role of STK39 in this Asian 
population more completely. As mentioned above, the study popu-
lation was not sufficiently large, and some important analyses did 
not obtain statistical significance. However, it was strength of the 
study to systemically analyze and present the association between 
STK39 variants and multiple cardiovascular risk factors. 
In conclusion, the associations between two SNPs of STK39, 
rs3754777 and rs6749447, and hypertension were not significant 
in this Korean cohort. However, we identified that AA genotype of 
rs3754777 had lower glucose and cholesterol levels, especially in 
females. Genotype of rs6749447 was associated with waist cir-
cumference, triglyceride, and HDL-C levels in gender stratified analy-
sis only. The genotype of rs6759447 was related to blood glucose 
levels. Further studies are needed to clarify the effect of STK39 vari-
ants in these cardiovascular risk factors. 
Acknowledgments
This study was supported by a grant (2009) from the Korean Soci-
ety of Cardiology and a faculty research grant of Yonsei University 
College of Medicine for 2012 (6-2012-0086).
References
1. Wang Y, O’Connell JR, McArdle PF, et al. From the Cover: whole-ge-
nome association study identifies STK39 as a hypertension susceptibil-
ity gene. Proc Natl Acad Sci U S A 2009;106:226-31.
2.  Delpire E, Gagnon KB. SPAK and OSR1: STE20 kinases involved in the 
regulation of ion homoeostasis and volume control in mammalian cells. 
Biochem J 2008;409:321-31.
3. Fava C, Danese E, Montagnana M, et al. Serine/threonine kinase 39 is a 
candidate gene for primary hypertension especially in women: results 
from two cohort studies in Swedes. J Hypertens 2011;29:484-91.
4. Chen LY, Zhao WH, Tian W, et al. STK39 is an independent risk factor 
for male hypertension in Han Chinese. Int J Cardiol 2012;154:122-7.
5. Newton-Cheh C, Johnson T, Gateva V, et al. Genome-wide association 
study identifies eight loci associated with blood pressure. Nat Genet 
2009;41:666-76.
6. Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood 
pressure and hypertension. Nat Genet 2009;41:677-87.
7. Cunnington MS, Kay C, Avery PJ, Mayosi BM, Koref MS, Keavney B. 
STK39 polymorphisms and blood pressure: an association study in 
British Caucasians and assessment of cis-acting influences on gene 
expression. BMC Med Genet 2009;10:135.
8. Niu WQ, Zhang Y, Ji KD, Gao PJ, Zhu DL. Contribution of five top wh-




Values p Values p Values  p
Triglyceride 0.99 0.06 0.04
AA 114 (76-192) 82 (68-158) 162 (91-225)
CA+CC 110 (83-161) 103 (81-150) 116 (86-169)
HDL-C 0.99 0.15 0.047
AA 49 (41-62) 50 (45-70) 40 (31-52)
CA+CC 48 (40-59) 52 (44-61) 45 (38-55)
LDL-C 0.16 0.32 0.25
AA 115 (95-134) 122 (96-136) 111 (95-133)
CC 120 (102-143) 121 (102-146) 119 (99-141)
hs-CRP 0.21 0.10 0.71
AA 0.55 (0.30-1.80) 0.72 (0.32-1.10) 0.51 (0.30-3.59)
CA+CC 0.46 (0.22-1.12) 0.38 (0.17-0.90) 0.62 (0.30-1.45)
Values are mean±SD or median (interquartile range). BP: blood pressure, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-cho-
lesterol, hs-CRP: high sensitivity C-reactive protein
19Dong-Jik Shin, et al.
http://dx.doi.org/10.4070/kcj.2013.43.1.13www.e-kcj.org
Hypertens 2011;25:278-80.
9. Rhee MY, Yang SJ, Oh SW, et al. Novel genetic variations associated 
with salt sensitivity in the Korean population. Hypertens Res 2011;34: 
606-11.
10. Mooser V, Waterworth D, Song KJ, Yuan X, Knouff CW, inventors; Glax-
oSmithKline Crop., assignee. Metabolic syndrome genetics. United 
States patent US 0203012 A1. 2009 Aug 13
11. Johnston AM, Naselli G, Gonez LJ, Martin RM, Harrison LC, DeAizpurua 
HJ. SPAK, a STE20/SPS1-related kinase that activates the p38 pathway. 
Oncogene 2000;19:4290-7.
12. Piechotta K, Garbarini N, England R, Delpire E. Characterization of the 
interaction of the stress kinase SPAK with the Na+-K+-2Cl- cotrans-
porter in the nervous system: evidence for a scaffolding role of the 
kinase. J Biol Chem 2003;278:52848-56.
13. Lee J, Sun C, Zhou Y, et al. p38 MAPK-mediated regulation of Xbp1s is 
crucial for glucose homeostasis. Nat Med 2011;17:1251-60.
14. Kushiyama A, Shojima N, Ogihara T, et al. Resistin-like molecule beta 
activates MAPKs, suppresses insulin signaling in hepatocytes, and in-
duces diabetes, hyperlipidemia, and fatty liver in transgenic mice on a 
high fat diet. J Biol Chem 2005;280:42016-25.
15. Ruixing Y, Jinzhen W, Shangling P, Weixiong L, Dezhai Y, Yuming C. Sex 
differences in environmental and genetic factors for hypertension. Am 
J Med 2008;121:811-9.
16. Qi H, Labrie Y, Grenier J, Fournier A, Fillion C, Labrie C. Androgens in-
duce expression of SPAK, a STE20/SPS1-related kinase, in LNCaP hu-
man prostate cancer cells. Mol Cell Endocrinol 2001;182:181-92.
20 STK39 Polymorphisms and Hypertension
http://dx.doi.org/10.4070/kcj.2013.43.1.13 www.e-kcj.org
Supplementary Table 1. Relative risk for hypertension based on genotype and haplotype of the studied variants (in subjects with age <50 years)
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Haplotype (rs3754777-rs6749447)
A-C/A-C vs.  A-C/Other+Other/Other 0.93 0.52-1.66 0.80 1.32 0.52-3.36 0.56 0.75 0.35-1.62 0.46
G-A/G-A vs. G-A/Other+Other/Other 1.13 0.64-1.99 0.68 0.83 0.34-2.01 0.68 1.44 0.67-3.11 0.35
G-C/G-C vs. G-C/Other+Other/Other 1.09 0.60-1.98 0.79 1.10 0.43-2.83 0.85 1.01 0.45-2.24 0.99
OR: odds ratio, CI: confidence interval
Supplementary Table 2. Association of genotype of rs3754777 and glucose and cholesterol (in subjects without glucose- or lipid lowering agents)
Total Female Male
Values p Values p Values p
Glucose 0.05 0.03 0.56
AA 78 (73-86) 78 (71-82) 82 (74-110)
GA+GG 84 (78-91) 82 (77-88) 86 (79-94)
Total cholesterol 0.03 0.04 0.35
AA 183 (156-205) 177 (156-201) 189 (155-212)
GA+GG 199 (176-222) 202 (178-227) 196 (175-213)
Values are median (interquartile range)
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Supplementary Table 3. Association between haplotype of the studied variants and parameters of cardiovascular risk
Haplotype (rs3754777-rs6749447)
Waist circumference
A-C vs. 79.8±7.0 0.17 75.5±6.8 0.07 83.7±4.7 0.63
Other 82.1±7.0 79.6±6.6 84.7±6.2
G-A vs. 80.7±7.3 0.14 77.1±6.6 0.05 84.9±5.6 0.83
Other 82.2±6.9 79.7±6.6 84.6±6.3
G-C vs. 82.3±7.1 0.60 79.0±7.0 0.68 84.8±6.3 0.84
Other 81.9±6.9 79.5±6.6 84.6±6.2
Systolic BP, adjusted
A-C vs. 126 (113-138) 0.45 123 (111-128) 0.14 133 (118-148) 0.76
Other 130 (117-142) 129 (114-142) 130 (119-142)
G-A vs. 123 (110-145) 0.16 118 (102-139) 0.11 124 (116-147) 0.83
Other 130 (118-142) 130 (115-142) 130 (119-142)
G-C vs. 130 (118-144) 0.98 133 (120-145) 0.06 124 (114-140) 0.06
Other 130 (116-141) 128 (113-140) 130 (120-144)
Diastolic BP, adjusted
A-C vs. 89 (75-97) 0.46 84 (74-90) 0.82 96 (80-100) 0.21
Other 84 (76-92) 82 (74-90) 84 (80-94)
G-A vs. 80 (75-91) 0.45 80 (69-90) 0.23 84 (80-98) 0.77
Other 84 (76-93) 84 (74-90) 85 (80-95)
G-C vs. 84 (80-94) 0.46 85 (80-95) 0.02 83 (78-90) 0.15
Other 84 (75-92) 80 (74-90) 86 (80-95)
Glucose
A-C vs. 78 (74-86) 0.05 78 (72-81) 0.02 82 (74-110) 0.56
Other 84 (78-91) 82 (77-89) 86 (79-94)
G-A vs. 82 (79-91) 0.63 81 (77-90) 0.67 86 (81-91) 0.77
Other 84 (78-91) 82 (77-88) 85 (78-94)
G-C vs. 85 (78-91) 0.84 82 (77-90) 0.63 85 (78-91) 0.30
Other 83 (78-91) 82 (77-88) 86 (79-94)
Total cholesterol
A-C vs. 183 (157-205) 0.04 177 (158-197) 0.04 189 (155-212) 0.41
Other 198 (175-222) 202 (178-227) 195 (174-213)
G-A vs. 193 (174-219) 0.51 198 (174-219) 0.50 185 (170-220) 0.70
Other 198 (175-222) 202 (177-226) 195 (174-212)
G-C vs. 194 (173-221) 0.51 195 (180-227) 0.78 191 (169-213) 0.68
Other 199 (175-222) 202 (176-225) 196 (174-214)
Triglyceride
A-C vs. 97 (77-153) 0.19 98 (81-106) 0.56 82 (75-188) 0.23
Other 112 (82-165) 102 (79-152) 126 (89-182)
G-A vs. 114 (76-192) 0.97 82 (68-158) 0.07 162 (91-225) 0.05
Other 110 (83-162) 103 (81-150) 117 (86-170)
G-C vs. 103 (82-165) 0.91 101 (79-161) 0.86 110 (86-168) 0.40
Other 112 (82-164) 101 (79-150) 130 (88-182)
HDL-C
A-C vs. 49 (46-57) 0.73 56 (47-64) 0.38 47 (36-52) 0.88
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Supplementary Table 3. Continued
Haplotype (rs3754777-rs6749447)
Other 48 (40-59) 52 (43-62) 45 (38-54)
G-A vs. 49 (41-62) 0.99 50 (45-70) 0.13 40 (31-52) 0.04
Other 48 (40-59) 52 (44-61) 45 (38-55)
G-C vs. 49 (39-60) 0.69 50 (40-60) 0.12 48 (39-65) 0.02
Other 48 (40-58) 52 (45-62) 44 (37-53)
LDL-C
A-C vs. 108 (96-131) 0.12 99 (96-125) 0.05 111 (96-140) 0.79
Other 120 (101-142) 122 (102-146) 118 (99-138)
G-A vs. 115 (95-134) 0.17 122 (96-136) 0.31 111 (95-133) 0.27
Other 120 (102-143) 121 (102-146) 119 (99-140)
G-C vs. 112 (100-138) 0.18 123 (102-154) 0.76 111 (94-130) 0.05
Other 121 (101-142) 121 (102-143) 120 (100-141)
hs-CRP
A-C vs. 0.72 (0.22-1.12) 0.52 0.64 (0.22-1.12) 0.63 0.78 (0.55-3.31) 0.46
Other 0.45 (0.23-1.15) 0.39 (0.18-0.95) 0.56 (0.30-1.46)
G-A vs. 0.55 (0.30-1.80) 0.20 0.72 (0.32-1.10) 0.09 0.51 (0.30-3.59) 0.70
Other 0.45 (0.22-1.12) 0.37 (0.17-0.88) 0.61 (0.30-1.45)
G-C vs. 0.40 (0.22-1.10) 0.44 0.34 (0.17-0.88) 0.70 0.45 (0.24-1.26) 0.19
Other 0.53 (0.23-1.14) 0.41 (0.19-0.99) 0.68 (0.34-1.83)
Values are mean±SD or median (interquartile range). BP: blood pressure, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-cho-
lesterol, hs-CRP: high sensitivity C-reactive protein
